The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma

Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early -stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence after adjuvant chemotherapy or who are likely to benefit from postoperative immunotherapy have remained unclear. Methods: This biomarker study (WJOG12219LTR) was designed to evaluate cancer stem cell markers (CD44 and CD133), programmed death-ligand 1 (PD -L1) expression on tumor cells, CD8 expression on tumor -infiltrating lymphocytes, and tumor mutation burden in completely resected stage II to IIIA NSCLC with the use of archived DNA and tissue samples from the prospective WJOG4107 trial. Tumors were classified as inflamed or noninflamed on the basis of the PD -L1 tumor proportion score and CD8 & thorn; tumorinfiltrating lymphocyte density. The association between each potential biomarker and relapse -free survival (RFS) during adjuvant chemotherapy was assessed by KaplanMeier analysis. Results: A total of 117 patients were included in this study. The median RFS was not reached (95% confidence intervals [CI]: 22.4 mo -not reached; n = 39) and 23.7 months (95% CI: 14.5 -43.6; n = 41) in patients with inflamed or noninflamed adenocarcinoma, respectively (log -rank p = 0.02, hazard ratio of 0.52 [95% CI: 0.29 -0.93]). Analysis of the combination of tumor inflammation category and TP53 mutation status revealed that inflamed tumors without TP53 mutations were associated with the longest RFS. Conclusions: PD -L1 expression on tumor cells, CD8 & thorn; T cell infiltration, and TP53 mutation status may help identify patients with early -stage NSCLC susceptible to recurrence after adjuvant chemotherapy. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).